Aberdeen Wealth Management LLC Buys Shares of 9,276 AbbVie Inc. $ABBV

Key Points

• Aberdeen Wealth Management initiated a position in AbbVie, purchasing 9,276 shares valued at approximately $2.33 million. Institutional investors collectively own 70.23% of the company.
• AbbVie exceeded quarterly expectations with $3.65 in earnings per share and $16.99 billion in revenue, while reaffirming 2026 adjusted EPS guidance of $13.87–$14.07. The company also pays a quarterly dividend of $1.73 per share, equivalent to a 2.7% yield.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $275.95 versus the reported share price of $260.69. Positive Phase 3 results for etentamig and the Apogee Therapeutics acquisition strengthen AbbVie’s pipeline, though acquisition costs may weigh on near-term earnings.

Aberdeen Wealth Management LLC bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,276 shares of the company's stock, valued at approximately $2,334,000. AbbVie makes up approximately 1.1% of Aberdeen Wealth Management LLC's investment portfolio, making the stock its 14th biggest position.

A number of other institutional investors have also modified their holdings of the company. Visionary Wealth Advisors purchased a new stake in shares of AbbVie during the second quarter worth about $14,980,000. Cullen Capital Management LLC purchased a new position in shares of AbbVie in the second quarter worth $1,800,000. Whalen Wealth Management Inc. purchased a new position in shares of AbbVie in the second quarter worth $931,000. Dearborn Partners LLC acquired a new stake in shares of AbbVie during the second quarter worth $27,926,000. Finally, Trail Ridge Investment Advisors LLC acquired a new stake in shares of AbbVie during the second quarter worth $525,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Price Performance

NYSE ABBV opened at $260.69 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The company has a market capitalization of $460.58 billion, a PE ratio of 73.64, a P/E/G ratio of 1.18 and a beta of 0.29. The company has a fifty day moving average of $254.57 and a 200 day moving average of $229.87.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio (DPR) is 195.48%.

Analyst Ratings Changes

Several research firms recently issued reports on ABBV. Piper Sandler upped their target price on AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. Guggenheim lifted their price target on AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Citigroup boosted their price target on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. increased their price objective on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Finally, Royal Bank Of Canada raised their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.95.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers positive Phase 3 results. AbbVie said its CERVINO trial met both primary endpoints in relapsed/refractory multiple myeloma. The treatment produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard therapies. The results support a potential new oncology growth driver and may allow AbbVie to compete for share in the increasingly competitive multiple myeloma market. AbbVie CERVINO Phase 3 results
• Positive Sentiment: Apogee expands AbbVie’s immunology pipeline. AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional programs targeting asthma and other inflammatory diseases. The deal strengthens AbbVie’s post-Humira growth prospects and diversifies its pipeline. AbbVie completes Apogee acquisition
• Neutral Sentiment: Full-year earnings guidance was reaffirmed. AbbVie maintained adjusted 2026 EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The range is broadly consistent with expectations, but its midpoint is slightly below the current consensus estimate of $14.02, limiting the immediate upside reaction.
• Negative Sentiment: Acquisition costs create near-term pressure. The Apogee transaction is expected to dilute earnings initially and become accretive only later, reportedly around 2032. Investors may therefore focus on the substantial cash commitment and the long wait before financial benefits fully materialize. AbbVie Apogee acquisition analysis

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company's stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.